Article

Phase 1a Evaluation of LP-184 in Recurrent Glioblastoma: Safety, Pharmacokinetics, and Translational Optimization of CNS Exposure

2026-04-24

Abstract excerpt

<h4>Purpose</h4> Limited CNS bioavailability and pharmacodynamics are obstacles to effective systemic therapies for glioblastoma. One strategy to overcome these challenges is drug combinations enhancing CNS penetration and/or tumor chemosensitivity. LP-184, a synthetic acylfulvene class alkylator, induces DNA damage and inhibits glioblastoma cell viability in pre-clinical models. LP-184 is a prodrug converted to...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: cc8c1db5-2671-5703-af6e-f430c08c536a
DOI: 10.64898/2026.04.21.26351406

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Phase 1a Evaluation of LP-184 in Recurrent Glioblastoma: Safety, Pharmacokinetics, and Translational Optimization of CNS ExposureDOI 10.64898/2026.04.21.26351406Read

Advances in Treatment of Isocitrate Dehydrogenase (IDH)-Wildtype Glioblastomas.Semantic proximity Read

EPIC-1042 as a potent PTRF/Cavin1–caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for glioblastomaSemantic proximity Read

A Genomically Tailored Multiagent Precision Medicine Clinical Trial for Adults with Recurrent Glioblastoma.Semantic proximity Read

Temozolomide and Other Alkylating Agents in Glioblastoma TherapySemantic proximity Read

Nanoarchaeosome-mediated epirubicin delivery induces sustained intracellular stress and suppresses adaptive glioblastoma phentoypesSemantic proximity Read

GBM radiosensitizers: dead in the water…or just the beginning?Semantic proximity Read

Targeting Metabolic and Epigenetic Vulnerabilities in Glioblastoma with SN-38 and Rabusertib Combination TherapySemantic proximity Read

Surgical window of opportunity trial reveals mechanisms of response and resistance to navtemadlin (KRT-232) in patients with recurrent glioblastomaSemantic proximity Read

Exploiting a metabolic vulnerability in brain tumour stem cells using a brain-penetrant drug with safe profileSemantic proximity Read

Role of PARP Inhibitors in Glioblastoma and Perceiving Challenges as Well as Strategies for Successful Clinical DevelopmentSemantic proximity Read

Temozolomide: Mechanisms of Action, Repair and ResistanceSemantic proximity Read

Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein responseSemantic proximity Read